Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2000-03-09
2001-06-12
Naff, David M. (Department: 1651)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C424S094640
Reexamination Certificate
active
06245548
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a novel method for the production of thrombin. More specifically, the present invention relates to a method for converting pure prothrombin or prothrombin free of other coagulating factors to thrombin by treating prothrombin with sodium citrate.
BACKGROUND OF THE INVENTION
The blood clotting cascade is activated when there is a change in the integrity of the blood circulatory system which results in the escape of blood. Generally, circulating platelet collect at the site of the wound, and upon exposure to air, the platelets rupture releasing the serine protease thromboplastin (Factor III). In the presence of vitamin K, Ca
++
ions and several other essential factors, thromboplastin catalyzes the conversion of prothrombin (Factor II) to thrombin, a serine protease with a molecular weight ranging from 36 kDa to 37 kDa. The newly formed thrombin catalyzes the hydrolysis of fibrinogen to form fibrin strands. The resulting fibrin in combination with activated platelets form a plug or clot to seal the wound, and contraction of the clot pulls the wound together preventing further bleeding (Clegg et al., Advanced biology principle and applications. London: John Murray Publishers, Ltd. (1994); Wallace et al., Biology: The science of life. Scott, Foresman and Company (1986)).
Thrombin can be formed from prothrombin in vitro by three known processes. One process involves incubating prothrombin with isolated thromboplastin in the presence of calcium chloride. This process is described, for example, in EP 0439156A. The disadvantage of using this method is that the thromboplastin typically employed is extracted from bovine lungs. The extraction process is time consuming and the resulting bovine thromboplastin can be contaminated with viruses or bacteria which carries the risk of transmitting infectious diseases. In addition, trace amounts of bovine thromboplastin that might be present in the resulting purified thrombin can cause immunological reactions in the host receiving thrombin produced by this method.
Another in vitro process for converting prothrombin to thrombin involves treating a mixture of prothrombin, Factor Xa, Factor Va and phospholipids with calcium ions. This process is described, for example, in U.S. Pat. Nos. 5,219,995 and 5,907,032. According to U.S. Pat. No. 5,907,032, the prothrombin mixture may also contain additional clotting factors, such as Factor X, Factor V, Factor IX, Factor IXa and trace amounts of thrombin. Thrombin produced in this manner has a specific activity ranging from about 250-700 U/mg. The requirement for additional clotting factors and the low specific activity are undesirable features of this process.
Similarly, in other processes, purified prothrombin is treated with activated Factor X, Factor V, phospholipid and calcium ions under physiological conditions to yield thrombin, or purified prothrombin is treated with 25% sodium citrate in the presence of coagulation factors such as Factor VIII, Factor IX and Factor X (Seegers, W. H.,
Proc. Soc. Exp. Biol. Med.,
72:677-80, 1949; Teng et al.,
Thrombosis Research,
22:203-12, 1981). The authors suggest that one or more of the various coagulating factors play a vital role in the process. Again, the requirement for additional clotting factors renders this process undesirable and inconvenient.
Still another in vitro process requires the use of snake venom to convert prothrombin to thrombin (Denson et al.
Toxicon,
7(1):5-11, 1969; Masci et al.
Biochem. Int.,
17(5):825-35, 1988; Rosing et al.
Toxicon,
30(12):1515-27, 1992; Stocker et al.
Toxicon,
32(10):1227-36, 1994). Snake venoms are classified into four groups based on their structure and function. Group I venoms convert prothrombin to an intermediate meizothrombin. Group II and III venoms cleave peptide bonds in prothrombin to produce thrombin. However, both Group II and III venoms require additional factor such as phospholipids, Factor Va and CaCl
2
. Group IV venoms convert prothrombin to an inactive form of thrombin (Rosing et al.,
Toxicon,
30(12):1515-27, 1992). The disadvantages to using snake venom are 1) it is difficult to obtain snake venom in large quantities, 2) some forms of snake venom convert prothrombin into enzymatically inactive forms of thrombin, and 3) traces of snake venom in thrombin preparation can be extremely harmful to the patient.
As discussed above, thrombin is an essential component of blood coagulation that acts during the final stages of the blood clotting process. Due to this function, thrombin is used clinically as a styptic agent. Additionally, thrombin functions as an activator of protein C, Factor V, platelets and proteins of the complement system. Thus, it is desirable to develop processes whereby thrombin can be easily produced and readily available. However, until now, there have been no commercially viable methods to efficiently and simply produce thrombin from pure prothrombin. Moreover, there have been no methods whereby workers could convert prothrombin to thrombin in the absence of coagulating factors or other activating enzymes. Accordingly, there is a need in the art for an efficient and simple non-enzymatic method for producing thrombin from pure prothrombin in the absence of additional coagulation factors.
SUMMARY OF THE INVENTION
To satisfy the need for an efficient and simple non-enzymatic method for producing thrombin and to avoid the numerous drawbacks of the methods described above, the inventors have developed a method for preparing enzymatically active thrombin from pure prothrombin. Specifically, the present invention provides a novel method for producing thrombin comprising treating pure isolated or recombinant prothrombin with sodium citrate.
REFERENCES:
Rossi et al., C. R. Acad. Sc. Paris., No. 2, vol. 268, pp. 418-419, 1969.*
Lanchantin et al., Journal of Biological Chemistry, vol. 240, No. 8, pp. 3276-3282, 1965.*
Cole et al., Canadian Journal of Biochemistry, vol. 44, No. 7, pp. 1051-1059, 1966.*
Cole, Thromb. Diath. Haemorrh., vol. 19, No. 3-4, pp. 321-333, 1968.*
Heldebrandt et al., Journal of Biological Chemistry, vol. 248, No. 10, pp. 3642-3652, 1973.
Drohan William N.
Ralston Annemarie H.
American National Red Cross
Burns, Swecker & Mathis, L.L.P.
Meller Michael V.
Naff David M.
LandOfFree
Activation of pure prothrombin to thrombin with about 30% to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activation of pure prothrombin to thrombin with about 30% to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activation of pure prothrombin to thrombin with about 30% to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2456259